Drug review fees in Europe to increase

03/11/2013 | In-PharmaTechnologist.com

The European Medicines Agency anticipates that fees for drug reviews will increase approximately 2.6% beginning in April, primarily to account for inflation. The EMA has also announced that it will reduce the current 75% fee reduction it offers for production of orphan drugs and use part of the additional revenue to fund salary and benefit increases.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA